Balyasny Asset Management
CAMP icon

Balyasny Asset Management’s CAMP4 Therapeutics CAMP Stock Holding History

Balyasny Asset Management’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Buy
2,632,437
+195,537
+8% +$928K 0.02% 969
2025
Q4 		$14.9M Buy
+2,436,900
New +$10.4M 0.02% 862

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Balyasny Asset Management's CAMP Position: Q1 2026 in Review

Balyasny Asset Management increased its CAMP4 Therapeutics (CAMP) stake by 8% in Q1 2026, buying an estimated $928K and bringing the position to 2,632,437 shares worth $11.6M. The position accounts for 0.02% of the portfolio, ranked #969.

Balyasny Asset Management first reported a position in CAMP in Q4 2025 and has held it in 2 quarters since. The position peaked at $14.9M in Q4 2025. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Balyasny Asset Management held 2,632,437 shares of CAMP4 Therapeutics worth $11.6M as of Q1 2026.
  • Balyasny Asset Management bought 195,537 CAMP4 Therapeutics shares in Q1 2026, an estimated $928K.
  • CAMP4 Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #969 holding.
  • Balyasny Asset Management first reported a position in CAMP4 Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Balyasny Asset Management's CAMP4 Therapeutics position peaked at $14.9M in Q4 2025.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.